• Scientists at McGill University and the Rosalind and Morris Goodman Cancer Institute have developed a new way to deliver cancer immunotherapy that caused fewer side effects compared to standard treatment in a preclinical study. • The work is published in the journal Proceedings of the National Academy of Sciences.
Article Summaries:
- Scientists at McGill University and the Rosalind and Morris Goodman Cancer Institute have engineered nanoparticles that target lymph nodes for cancer immunotherapy. In a preclinical study, the new delivery system produced fewer side effects than conventional treatments, according to findings published in the Proceedings of the National Academy of Sciences. The approach uses specially designed particles to concentrate therapeutic agents in lymphatic tissue, potentially improving efficacy while reducing systemic toxicity. Researchers suggest the technology could enhance treatment of cancers that spread to lymph nodes, though clinical trials are needed to confirm safety and effectiveness in humans.
Sources: